NVCT — Nuvectis Pharma Share Price
0.000.00%
Last trade - 00:00- $116.19m
- $96.73m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.23 | ||
| Price to Tang. Book | 9.23 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -165.4% | ||
| Return on Equity | -170.23% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing two drug candidates: NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- July 27th, 2020
- Public Since
- February 4th, 2022
- No. of Shareholders
- 45
- No. of Employees
- 13
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 18,356,060
- Address
- 1 Bridge Plaza, Suite 275, FORT LEE, 07024
- Web
- https://nuvectis.com/
- Phone
- +1 3608377232
- Auditors
- Kesselman & Kesselman
Upcoming Events for NVCT
Similar to NVCT
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Nuvectis Pharma share price?
As of Today at 22:26 UTC, shares in Nuvectis Pharma are trading at $7.05. This share price information is delayed by 15 minutes.
How has the Nuvectis Pharma share price performed this year?
Shares in Nuvectis Pharma last closed at $7.05 and the price had moved by -60.24% over the past 365 days. In terms of relative price strength the Nuvectis Pharma share price has underperformed the S&P500 Index by -68.36% over the past year.
What are the analyst and broker recommendations for Nuvectis Pharma?
The overall consensus recommendation for Nuvectis Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Nuvectis Pharma dividend yield?
Nuvectis Pharma does not currently pay a dividend.
Does Nuvectis Pharma pay a dividend?
Nuvectis Pharma does not currently pay a dividend.
When does Nuvectis Pharma next pay dividends?
Nuvectis Pharma does not currently pay a dividend.
How do I buy Nuvectis Pharma shares?
To buy shares in Nuvectis Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nuvectis Pharma?
As of the previous close price of $7.05, shares in Nuvectis Pharma had a market capitalisation of $129.41m.
Where are Nuvectis Pharma shares listed?
Here are the trading details for Nuvectis Pharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: NVCT
What kind of share is Nuvectis Pharma?
Based on an overall assessment of its quality, value and momentum Nuvectis Pharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nuvectis Pharma share price forecast for 2024?
The analyst consensus target price for shares in Nuvectis Pharma is $22.00. That is 212.06% above the last closing price of $7.05.
Analysts covering Nuvectis Pharma currently have a consensus Earnings Per Share (EPS) forecast of -$1.14 for the next financial year.
What is the trend in the Nuvectis Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nuvectis Pharma. Over the past six months, its share price has underperformed the S&P500 Index by -25.87%.
As of the last closing price of $7.05, shares in Nuvectis Pharma were trading -18.31% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nuvectis Pharma PE Ratio?
The Nuvectis Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $7.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nuvectis Pharma?
We do not have data on Nuvectis Pharma's directors